Limits...
Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.

Zhang M, Jiao Y, Wang S, Zhang L, Huang Z, Chen Y, Wu H - PLoS ONE (2012)

Bottom Line: Such cross neutralizing activity took 1-2 years to develop and CD4 binding site antibodies were critical components in these blood samples.Our study confirmed the presence of broadly neutralizing sera in China's HIV-1 patient population.Understanding the specificity and breadth of these neutralizing activities can guide efforts for the development of HIV vaccines against major HIV-1 viruses in China.

View Article: PubMed Central - PubMed

Affiliation: Jiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

ABSTRACT
Protective antibodies play a critical role in an effective HIV vaccine; however, eliciting antibodies to block infection by viruses from diverse genetic subtypes remains a major challenge. As the world's most populous country, China has been under the threat of at least three major subtypes of circulating HIV-1 viruses. Understanding the cross reactivity and specificities of serum antibody responses that mediate broad neutralization of the virus in HIV-1 infected Chinese patients will provide valuable information for the design of vaccines to prevent HIV-1 transmission in China. Sera from a cohort of homosexual men, who have been managed by a major HIV clinical center in Beijing, China, were analyzed for cross-sectional neutralizing activities against pseudotyped viruses expressing Env antigens of the major subtype viruses (AE, BC and B subtypes) circulating in China. Neutralizing activities in infected patients' blood were most capable of neutralizing viruses in the homologous subtype; however, a subset of blood samples was able to achieve broad neutralizing activities across different subtypes. Such cross neutralizing activity took 1-2 years to develop and CD4 binding site antibodies were critical components in these blood samples. Our study confirmed the presence of broadly neutralizing sera in China's HIV-1 patient population. Understanding the specificity and breadth of these neutralizing activities can guide efforts for the development of HIV vaccines against major HIV-1 viruses in China.

Show MeSH

Related in: MedlinePlus

Subtype specificity of NAb responses identified in HIV-1 infected patients’ sera.Neutralization against pseudotyped viruses expressing primary Env from subtypes B, BC, C, and AE isolates were tested. Percentage of neutralization by patients’ sera (at 1∶20 dilution) infected with one of three viral subtypes (B, BC, and AE as shown in panels A, B, and C, respectively) were calculated. The significant differences (p<0.05) of neutralizing activities between different groups of patient sera are indicated.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3475692&req=5

pone-0047548-g002: Subtype specificity of NAb responses identified in HIV-1 infected patients’ sera.Neutralization against pseudotyped viruses expressing primary Env from subtypes B, BC, C, and AE isolates were tested. Percentage of neutralization by patients’ sera (at 1∶20 dilution) infected with one of three viral subtypes (B, BC, and AE as shown in panels A, B, and C, respectively) were calculated. The significant differences (p<0.05) of neutralizing activities between different groups of patient sera are indicated.

Mentions: When a more quantitative analysis was conducted by combining all positive neutralizing activities together (both red and yellow (50–74% inhibition) boxes, serum samples from subtype B patients had the highest percentage of neutralization against subtype B viruses, which was significantly higher than the subtypes BC (p = 0.002) and AE (p = 0.015) (Fig. 2A). Subtype BC patient sera neutralized more subtype C than the subtypes B, BC, or AE (p = 0.04, p = 0.003, and p = 0.0001, respectively) (Fig. 2B). Serum samples from subtype AE patients neutralized more subtype AE viruses than subtypes B, C, and BC (p = 0.0034, p = 0.004, and p = 0.014 respectively) (Fig. 2C). Our data demonstrated that, in general, HIV-1-infected patient sera tend to have the best neutralizing activities against viruses from the autogolous subtype but there is a low frequency of cross-subtype neutralizing activities, more likely with sera from patients infected with subtypes B and BC viruses.


Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.

Zhang M, Jiao Y, Wang S, Zhang L, Huang Z, Chen Y, Wu H - PLoS ONE (2012)

Subtype specificity of NAb responses identified in HIV-1 infected patients’ sera.Neutralization against pseudotyped viruses expressing primary Env from subtypes B, BC, C, and AE isolates were tested. Percentage of neutralization by patients’ sera (at 1∶20 dilution) infected with one of three viral subtypes (B, BC, and AE as shown in panels A, B, and C, respectively) were calculated. The significant differences (p<0.05) of neutralizing activities between different groups of patient sera are indicated.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3475692&req=5

pone-0047548-g002: Subtype specificity of NAb responses identified in HIV-1 infected patients’ sera.Neutralization against pseudotyped viruses expressing primary Env from subtypes B, BC, C, and AE isolates were tested. Percentage of neutralization by patients’ sera (at 1∶20 dilution) infected with one of three viral subtypes (B, BC, and AE as shown in panels A, B, and C, respectively) were calculated. The significant differences (p<0.05) of neutralizing activities between different groups of patient sera are indicated.
Mentions: When a more quantitative analysis was conducted by combining all positive neutralizing activities together (both red and yellow (50–74% inhibition) boxes, serum samples from subtype B patients had the highest percentage of neutralization against subtype B viruses, which was significantly higher than the subtypes BC (p = 0.002) and AE (p = 0.015) (Fig. 2A). Subtype BC patient sera neutralized more subtype C than the subtypes B, BC, or AE (p = 0.04, p = 0.003, and p = 0.0001, respectively) (Fig. 2B). Serum samples from subtype AE patients neutralized more subtype AE viruses than subtypes B, C, and BC (p = 0.0034, p = 0.004, and p = 0.014 respectively) (Fig. 2C). Our data demonstrated that, in general, HIV-1-infected patient sera tend to have the best neutralizing activities against viruses from the autogolous subtype but there is a low frequency of cross-subtype neutralizing activities, more likely with sera from patients infected with subtypes B and BC viruses.

Bottom Line: Such cross neutralizing activity took 1-2 years to develop and CD4 binding site antibodies were critical components in these blood samples.Our study confirmed the presence of broadly neutralizing sera in China's HIV-1 patient population.Understanding the specificity and breadth of these neutralizing activities can guide efforts for the development of HIV vaccines against major HIV-1 viruses in China.

View Article: PubMed Central - PubMed

Affiliation: Jiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

ABSTRACT
Protective antibodies play a critical role in an effective HIV vaccine; however, eliciting antibodies to block infection by viruses from diverse genetic subtypes remains a major challenge. As the world's most populous country, China has been under the threat of at least three major subtypes of circulating HIV-1 viruses. Understanding the cross reactivity and specificities of serum antibody responses that mediate broad neutralization of the virus in HIV-1 infected Chinese patients will provide valuable information for the design of vaccines to prevent HIV-1 transmission in China. Sera from a cohort of homosexual men, who have been managed by a major HIV clinical center in Beijing, China, were analyzed for cross-sectional neutralizing activities against pseudotyped viruses expressing Env antigens of the major subtype viruses (AE, BC and B subtypes) circulating in China. Neutralizing activities in infected patients' blood were most capable of neutralizing viruses in the homologous subtype; however, a subset of blood samples was able to achieve broad neutralizing activities across different subtypes. Such cross neutralizing activity took 1-2 years to develop and CD4 binding site antibodies were critical components in these blood samples. Our study confirmed the presence of broadly neutralizing sera in China's HIV-1 patient population. Understanding the specificity and breadth of these neutralizing activities can guide efforts for the development of HIV vaccines against major HIV-1 viruses in China.

Show MeSH
Related in: MedlinePlus